Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance

Benzer Materyaller

• Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy
  Yazar:: Shi, Jinpeng, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
  Yazar:: Liu, Sangtian, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
  Yazar:: Jia, Yijun, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Novel agents and strategies for overcoming EGFR TKIs resistance
  Yazar:: Niu, Fei-Yu, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer
  Yazar:: WANG, CHENGDE, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)